Abstract 1576P
Background
In Italy, progress in lung cancer mortality in men is not paralleled by similar trends in women, though exposure to tobacco smoking is well known to be the key driver of lung cancer incidence and mortality. This study aimed to compare recent trends in lung cancer mortality rates in Italian men and women.
Methods
Mortality data for 2003-2019 were retrieved from death certificates compiled by the Italian National Institute for Statistics. These data were used to compute, separately in men and women, age-standardized mortality rates (/105/year) for lung cancer (ICD-10: C33-C34.9). Furthermore, we estimated the absolute number of prevented lung cancer deaths in 2007-2019 in Italy, as the difference between the observed and expected (based on the 2003-2006 mortality rates) number of lung cancer deaths. Data on the prevalence of tobacco smoking in men and women were collected from national surveys.
Results
In Italian men, the use of tobacco smoking strongly declined from 60% in the 1960s to 27.7% in 2021, whereas it tended to increase in women – particularly in the two last decades from 16.6% in 2004 to 20.7% in 2021. In men, a decline from 2007 to 2019 in lung cancer mortality rates was documented in all geographic areas (e.g., from 121.2/105 to 92.6/105 in northern Italy; and from 98.5/105 to 91.4/105 in southern Italy). Conversely, upward trends were registered for women: from 30.3/105 to 33.8/105 in the North; and from 16.3/105 to 20.3/105 in the South. From 2007 to 2019, there was an 18.7% reduction in the expected number of lung cancer deaths in men (-73.397) and an increase of 16.0% in expected deaths in women (+16.036).
Conclusions
Study findings strengthen the persistent need for tailoring interventions to reduce smoking among females to invert lung cancer mortality trends in Italian women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health, Ricerca Corrente IRCCS CRO, Aviano.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10